Stereotactic body radiotherapy versus radiofrequency ablation for hepatocellular carcinoma: a systematic review and meta-analysis

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Benson AB, D'Angelica MI, Abbott DE, et al. Guidelines insights: hepatobiliary cancers, version 2.2019. J Natl Compr Canc Netw. 2019;17(4):302–310.
   PubMed Web of Science ®Google Scholar
• Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–380.
   PubMed Web of Science ®Google Scholar
• Tanaka K, Kojima T, Hiraguchi E, et al. Laparoscopy-guided transthoracic transdiaphragmatic radiofrequency ablation for hepatic tumors located beneath the diaphragm. J Laparoendosc Adv Surg Tech A. 2016;26(3):180–184.
   PubMed Web of Science ®Google Scholar
• Al-Alem I, Pillai K, Akhter J, et al. Heat sink phenomenon of bipolar and monopolar radiofrequency ablation observed using polypropylene tubes for vessel simulation. Surg Innov. 2014;21(3):269–276.
   PubMed Web of Science ®Google Scholar
• Kim JW, Seong J, Lee IJ, et al. Phase I dose escalation study of helical intensity-modulated radiotherapy-based stereotactic body radiotherapy for hepatocellular carcinoma. Oncotarget. 2016;7(26):40756–40766.
   PubMedGoogle Scholar
• Bujold A, Massey CA, Kim JJ, et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol. 2013;31(13):1631–1639.
   PubMed Web of Science ®Google Scholar
• Cardenes HR, Price TR, Perkins SM, et al. Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol. 2010;12(3):218–225.
   PubMed Web of Science ®Google Scholar
• Hass P, Mohnike K. Extending the frontiers beyond thermal ablation by radiofrequency ablation: SBRT, brachytherapy, SIRT (radioembolization). Viszeralmedizin. 2014;30(4):245–252.
   PubMedGoogle Scholar
• Qi WX, Fu S, Zhang Q, et al. Charged particle therapy versus photon therapy for patients with hepatocellular carcinoma: a systematic review and meta-analysis. Radiother Oncol. 2015;114(3):289–295.
   PubMed Web of Science ®Google Scholar
• Kim N, Cheng J, Jung I, et al. Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma. J Hepatol. 2020;73(1):121–129.
   PubMed Web of Science ®Google Scholar
• Hara K, Takeda A, Tsurugai Y, et al. Radiotherapy for hepatocellular carcinoma results in comparable survival to radiofrequency ablation: a propensity score analysis. Hepatology. 2019;69(6):2533–2545.
   PubMed Web of Science ®Google Scholar
• Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.
   PubMed Web of Science ®Google Scholar
• Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statist. Med. 1998;17(24):2815–2834.
   PubMed Web of Science ®Google Scholar
• Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–605.
   PubMed Web of Science ®Google Scholar
• Deeks JJ, Higgins JP, Altman DG. Analysing data and undertaking meta‐analyses. In: Higgins JPT, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions, Second Edition. Glasgow: John Wiley and Sons; 2019. Chapter 10, p. 241–284.
   Google Scholar
• Soin AS, Bhangui P, Kataria T, et al. Experience with LDLT in patients with hepatocellular carcinoma and portal vein tumor thrombosis postdownstaging. Transplantation. 2020; 104(11):2334–2345.
   Web of Science ®Google Scholar
• Kim N, Kim HJ, Won JY, et al. Retrospective analysis of stereotactic body radiation therapy efficacy over radiofrequency ablation for hepatocellular carcinoma. Radiother Oncol. 2019;131:81–87.
   PubMed Web of Science ®Google Scholar
• Rajyaguru DJ, Borgert AJ, Smith AL, et al. Radiofrequency ablation versus stereotactic body radiotherapy for localized hepatocellular carcinoma in nonsurgically managed patients: analysis of the national cancer database. J Cin Oncol. 2018;36(6):600–608.
   PubMed Web of Science ®Google Scholar
• Parikh ND, Marshall VD, Green M, et al. Effectiveness and cost of radiofrequency ablation and stereotactic body radiotherapy for treatment of early-stage hepatocellular carcinoma: an analysis of SEER-medicare. J Med Imaging Radiat Oncol. 2018;62(5):673–681.
   PubMed Web of Science ®Google Scholar
• Wahl DR, Stenmark MH, Tao Y, et al. Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma. J Cin Oncol. 2016;34(5):452–459.
   PubMed Web of Science ®Google Scholar
• Shiozawa K, Watanabe M, Ikehara T, et al. Comparison of percutaneous radiofrequency ablation and CyberKnife(®) for initial solitary hepatocellular carcinoma: a pilot study. World J Gastroenterol. 2015;21(48):13490–13499.
   PubMed Web of Science ®Google Scholar
• Park HC, Yu JI, Cheng JC, et al. Consensus for radiotherapy in hepatocellular carcinoma from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014): current practice and future clinical trials. Liver Cancer. 2016;5(3):162–174.
   PubMed Web of Science ®Google Scholar
• Pollom EL, Lee K, Durkee BY, et al. Cost-effectiveness of stereotactic body radiation therapy versus radiofrequency ablation for hepatocellular carcinoma: a markov modeling study. Radiology. 2017;283(2):460–468.
   PubMed Web of Science ®Google Scholar
• Nault JC, Sutter O, Nahon P, et al. Percutaneous treatment of hepatocellular carcinoma: state of the art and innovations. J Hepatol. 2018;68(4):783–797.
   PubMed Web of Science ®Google Scholar
• Sapisochin G, Barry A, Doherty M, et al. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis. J Hepatol. 2017;67(1):92–99.
   PubMed Web of Science ®Google Scholar
• Mohamed M, Katz AW, Tejani MA, et al. Comparison of outcomes between SBRT, yttrium-90 radioembolization, transarterial chemoembolization, and radiofrequency ablation as bridge to transplant for hepatocellular carcinoma. Adv Radiat Oncol. 2016;1(1):35–42.
   PubMedGoogle Scholar
• Rim CH, Kim HJ, Seong J. Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinoma: a systematic review and meta-analysis of observational studies. Radiother Oncol. 2019;131:135–144.
   PubMed Web of Science ®Google Scholar
• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–1314.
   PubMed Web of Science ®Google Scholar
• Tabrizian P, Jibara G, Shrager B, et al. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg. 2015;261(5):947–955.
   PubMed Web of Science ®Google Scholar
• Folkert MR, Timmerman RD. Stereotactic ablative body radiosurgery (SABR) or Stereotactic body radiation therapy (SBRT). Adv Drug Deliv Rev. 2017;109:3–14.
   PubMed Web of Science ®Google Scholar
• Herfarth KK, Debus J, Lohr F, et al. Extracranial stereotactic radiation therapy: set-up accuracy of patients treated for liver metastases. Int J Radiat Oncol Biol Phys. 2000;46(2):329–335.
   PubMed Web of Science ®Google Scholar
• Guckenberger M, Richter A, Boda-Heggemann J, et al. Motion compensation in radiotherapy. Crit Rev Biomed Eng. 2012;40(3):187–197.
   PubMedGoogle Scholar
• Guckenberger M, Wilbert J, Krieger T, et al. Four-dimensional treatment planning for stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 2007;69(1):276–285.
   PubMed Web of Science ®Google Scholar
• Saito T, Sakamoto T, Oya N. Comparison of gating around end-expiration and end-inspiration in radiotherapy for lung cancer. Radiother Oncol. 2009;93(3):430–435.
   PubMed Web of Science ®Google Scholar
• Kontrisova K, Stock M, Dieckmann K, et al. Dosimetric comparison of stereotactic body radiotherapy in different respiration conditions: a modeling study. Radiother Oncol. 2006;81(1):97–104.
   PubMed Web of Science ®Google Scholar
• Guckenberger M, Meyer J, Wilbert J, et al. Precision of image-guided radiotherapy (IGRT) in six degrees of freedom and limitations in clinical practice. Strahlenther Onkol. 2007;183(6):307–313.
   PubMed Web of Science ®Google Scholar
• Keall PJ, Cattell H, Pokhrel D, et al. Geometric accuracy of a real-time target tracking system with dynamic multileaf collimator tracking system. Int J Radiat Oncol Biol Phys. 2006;65(5):1579–1584.
   PubMed Web of Science ®Google Scholar
• Klein J, Dawson LA, Jiang H, et al. Prospective longitudinal assessment of quality of life for liver cancer patients treated with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2015;93(1):16–25.
   PubMed Web of Science ®Google Scholar